Latest Trustworthy News from Dr. Mercola - delivered straight to your inbox!

New Cancer Screening Advice Comes With a Catch

New prostate cancer screening recommendations are renewing an important conversation about early detection and the potential consequences of routine testing. The American Cancer Society has updated its guidelines to recommend more regular prostate-specific antigen (PSA) testing for many men, citing evidence that screening can reduce prostate cancer deaths. However, PSA screening has long been controversial because an elevated result doesn't necessarily mean a man has cancer, and additional testing can sometimes lead to unnecessary procedures or treatment for cancers that may never have caused harm.

Under the updated guidelines, the American Cancer Society recommends PSA testing every two years beginning at age 50 for men at average risk and annually beginning at age 45 for those at higher risk. For men ages 70 to 74, the organization recommends individualized decisions about screening. The changes were influenced partly by long-term research associating regular PSA screening with a 13% reduction in prostate cancer deaths over 23 years. However, screening is only the first step in a potentially complicated process. PSA levels can rise for reasons unrelated to cancer, and detecting a slow-growing tumor may lead to treatment that carries risks such as urinary incontinence and erectile dysfunction.

Rather than treating an elevated PSA result as an automatic reason for invasive testing or immediate treatment, men should understand their options and the possible consequences of each decision. Repeating an elevated PSA test and considering additional evaluations, such as prostate MRI or appropriate biomarker testing, may help determine whether a biopsy is necessary. If cancer is diagnosed, its aggressiveness, stage and individual circumstances should guide discussions about treatment, including whether active surveillance is appropriate. The updated guidelines underscore the potential value of detecting aggressive cancers earlier, but they don't eliminate the importance of avoiding unnecessary intervention. Ultimately, informed decisions about prostate health require weighing both the potential benefits of screening and the risks of what may follow.

 

SOURCE:

Healthline, November 16, 2026

Mercola, December 07, 2015